Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of BG505 SOSIP.GT1.1 gp140 HIV Vaccine in Healthy Adults
NCT04224701Phase 1Completed
- Sponsor
- International AIDS Vaccine Initiative
- Start
- Aug 2020
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of BG505 SOSIP GT1.1 gp140 in human immunodeficiency virus infection (HIV) (2 cohorts), sponsored by International AIDS Vaccine Initiative. Primary endpoints: Safety - reactogenicity at 7 days, Safety - IP related unsolicited adverse events at 28 days and 3 more. Started Aug 2020; status: completed.
02
Drugs
BG505 SOSIP GT1.1 gp140
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04224701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04224701.